Key takeaways:
- Knowledge from sufferers with moist AMD who acquired 9 injections of faricimab had been analyzed.
- Examine outcomes instructed speedy enhancements in anatomy in each beforehand handled and treatment-naïve sufferers.
SALT LAKE CITY — Faricimab demonstrated “speedy enhancements” in anatomic options throughout beforehand handled and treatment-naïve sufferers, based on 3-year research outcomes.
“The TRUCKEE research is a real-world research investigating the efficacy and security of faricimab in neovascular age-related macular degeneration,” Hannah Khan, MPH, instructed Healio on the Affiliation for Analysis in Imaginative and prescient and Ophthalmology assembly. “We at the moment are at 3 years, and we’re seeing upkeep in imaginative and prescient and fluid standing.”
Picture: Alex Younger
Khan and colleagues carried out a retrospective chart assessment of sufferers collaborating within the TRUCKEE research.
“We’re growing our knowledge set by way of what number of sufferers are concerned on this research, and we’re seeing long-term follow-up,” she mentioned. “Proper now we’re 9 injections of faricimab with fairly vital upkeep of fluid and imaginative and prescient.”
Sufferers who acquired 9 injections of faricimab had been stratified into three teams: all-switch (n = 436), aflibercept-switch (n = 269) and treatment-naïve (n = 61). Outcomes confirmed that the advantages from faricimab elevated with steady remedy. The charges of idiopathic orbital irritation and endophthalmitis had been low, and just one case of nonocclusive vasculitis was reported. Moreover, numerous sufferers confirmed full decision of intraretinal or subretinal fluid.
“We’re additionally seeing an extension of remedy intervals,” Khan mentioned. “As we transfer on via the research and we improve sufferers’ injections, we’re in a position to lengthen their intervals between injections.”
Sources/Disclosures
Collapse
Khan H, et al. The TRUCKEE research: Actual-world efficacy and security of faricimab in neovascular AMD – 3 yr outcomes. Introduced at: Affiliation for Analysis in Imaginative and prescient and Ophthalmology assembly; Might 4-8, 2025; Salt Lake Metropolis.
Disclosures:
Khan reviews having been employed by Genentech.
